scholarly journals Rapid Review on Multiple Myeloma; Current Clinical Management

2022 ◽  
pp. 134-140
Author(s):  
Sepideh Khazeni ◽  
Bahareh Bigdeli
Keyword(s):  
Multiple Myeloma ◽  
Clinical Management ◽  
Rapid Review

scholarly journals The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma

2020 ◽  
Vol 99 (8) ◽  
pp. 1709-1725
Author(s):  
Maximilian Merz ◽  
Tobias Dechow ◽  
Mithun Scheytt ◽  
Christian Schmidt ◽  
Bjoern Hackanson ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Management ◽  
Newly Diagnosed

scholarly journals Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma

2020 ◽  
Vol 21 (20) ◽  
pp. 7539
Author(s):  
Amro M. Soliman ◽  
Teoh Seong Lin ◽  
Pasuk Mahakkanukrauh ◽  
Srijit Das
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Tumor Growth ◽  
Malignant Transformation ◽  
Bone Disease ◽  
Clinical Management ◽  
Potential Role ◽  
Plasma Cells ◽  
The Usa

Multiple myeloma (MM) is a cancerous bone disease characterized by malignant transformation of plasma cells in the bone marrow. MM is considered to be the second most common blood malignancy, with 20,000 new cases reported every year in the USA. Extensive research is currently enduring to validate diagnostic and therapeutic means to manage MM. microRNAs (miRNAs) were shown to be dysregulated in MM cases and to have a potential role in either progression or suppression of MM. Therefore, researchers investigated miRNAs levels in MM plasma cells and created tools to test their impact on tumor growth. In the present review, we discuss the most recently discovered miRNAs and their regulation in MM. Furthermore, we emphasized utilizing miRNAs as potential targets in the diagnosis, prognosis and treatment of MM, which can be useful for future clinical management.

scholarly journals The molecular characterization and clinical management of multiple myeloma in the post-genome era

Leukemia ◽  
2009 ◽  
Vol 23 (11) ◽  
pp. 1941-1956 ◽  
Author(s):  
Y Zhou ◽  
B Barlogie ◽  
J D Shaughnessy
Keyword(s):  
Multiple Myeloma ◽  
Molecular Characterization ◽  
Clinical Management

Current Concepts of Clinical Management of Multiple Myeloma

2012 ◽  
Vol 58 (4) ◽  
pp. 195-207 ◽  
Author(s):  
Sai Ravi Pingali ◽  
Rami Y. Haddad ◽  
Ayman Saad
Keyword(s):  
Multiple Myeloma ◽  
Clinical Management

Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma

2019 ◽  
Vol 19 (5) ◽  
pp. e228-e237 ◽  
Author(s):  
Hélène Caillon ◽  
Hervé Avet-Loiseau ◽  
Michel Attal ◽  
Philippe Moreau ◽  
Olivier Decaux ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Light Chain ◽  
Clinical Management ◽  
Free Light Chain

scholarly journals High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment

2019 ◽  
Author(s):  
Antonio Giovanni Solimando ◽  
Matteo Claudio Da Vià ◽  
Sebastiano Cicco ◽  
Patrizia Leone ◽  
Giuseppe Di Lernia ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
High Risk ◽  
Clinical Management ◽  
The Novel ◽  
Great Efficacy ◽  
Angiogenic Therapy ◽  
Risk Profiling ◽  
Comprehensive Knowledge ◽  
Molecular Determinants ◽  
Druggable Targets

Multiple myeloma (MM) is a genetically heterogenous disease that includes a subgroup of 10-15% of patients facing dismal survival despite most intensive treatment. The aim of this review article is to provide an integrated clinical and biological overview on the high-risk MM discussing the novel therapeutic perspectives aimed to target the neoplastic clone and its microenvironment. The dissection of the molecular determinants of the aggressive phenotypes and drug resistance can foster a better tailored clinical management of high-risk profile and refractoriness to therapy. Among the current clinical difficulties in MM, patient’s management manipulating the tumor niche represents a major challenge given the limited knowledge about the MM-milieu interaction. The angiogenesis and bystander infiltrate constitute pivotal mechanisms of mutual collaboration between MM and the non-tumoral counterpart. Immuno-modulatory and anti-angiogenic therapy hold great efficacy but variable and unpredictable responses in high-risk MM. Therefore, it would be worth to better select the population and the MM stage that could profit to a dual immune/vasculogenesis targeting. The comprehensive knowledge of the genetic heterogeneity and MM high-risk ecosystem enforce a systematic bench-to-bedside approach. Despite significant improvements in the biology knowledge, MM is still a chronic and incurable neoplasia and therapeutic options able to overcome the relapsing/refractory behavior represent an unmet clinical need. Here, we corroborate previous biological findings providing a synthetic outlook of novel druggable targets. We also summarize the existing multi-omics-based risk profiling tools, in order to better personalize the patient-oriented clinical management.

Impact of telemedicine on diagnosis, clinical management and outcomes in rural trauma patients: A rapid review

2020 ◽  
Vol 25 (1) ◽  
pp. 31 ◽  
Author(s):  
Richard Fleet ◽  
Luc Lapointe ◽  
Marie-Helene Lavallee-Bourget ◽  
Alexia Pichard-Jolicoeur ◽  
Catherine Turgeon-Pelchat
Keyword(s):  
Clinical Management ◽  
Rapid Review ◽  
Trauma Patients

scholarly journals Gamapatias Monoclonais de Significado Indeterminado: Critérios de Diagnóstico e Acompanhamento Clínico

2014 ◽  
Vol 27 (5) ◽  
pp. 661
Author(s):  
Joana Parreira ◽  
Paulo Lúcio ◽  
Cristina João ◽  
Ana Macedo ◽  
Ana Bela Sarmento ◽  
...  
Keyword(s):  
Risk Factors ◽  
Multiple Myeloma ◽  
Clinical Management ◽  
Monoclonal Gammopathy ◽  
Long Term Care ◽  
Term Care ◽  
Monoclonal Gammopathies ◽  
Undetermined Significance

<p>The Portuguese group of multiple myeloma of the Portuguese Society of Hematology proposes a national protocol for diagnosis and clinical follow-up of monoclonal gammopathies. The proposed protocol aims to standardize clinical management of monoclonal gammopathies. Furthermore, it would also define the major risk factors for progression to Multiple Myeloma that require a precocious close articulation between general practitioners and a Hematology Clinic.</p><p><br /><strong>Keywords: </strong>Monoclonal Gammopathy of Undetermined Significance; Prognosis; Disease Progression; Long-Term Care; Portugal.</p>

Sign in / Sign up

Export Citation Format

Share Document